Phase 3 Alzheimer’s disease clinical trial for potential add-on therapy to Donepezil (Aricept) at University Hospitals

Wednesday, August 10, 2016
CLEVELAND — University Hospitals Case Medical Center is participating in a Phase III clinical research study, called MINDSET, to evaluate the effectiveness of a potential new treatment option for people with mild-to-moderate Alzheimer’s disease.  The investigational drug, RVT-101, is being tested as an add-on therapy to donepezil (brand name Aricept®). Alan Lerner, MD, Director of the Brain Health and Memory Center at UH, is the principal investigator of the study in Cleveland.
MINDSET is an international, multi-center, double blind, placebo-controlled study designed to evaluate the safety, efficacy and tolerability of RVT-101.  The 24-week trial will compare RVT-101 to placebo in approximately 1,150 people with mild-to-moderate Alzheimer’s disease. All study participants will remain on donepezil therapy during the trial.  

Download full release

<< Back

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.